Atara Biotherapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 4.19 million. Revenue was USD 4.25 million compared to USD 0.221 million a year ago. Net loss was USD 60.45 million compared to USD 74.57 million a year ago. Basic loss per share from continuing operations was USD 14 compared to USD 18 a year ago.
For the full year, sales was USD 7.89 million. Revenue was USD 8.57 million compared to USD 63.57 million a year ago. Net loss was USD 276.13 million compared to USD 228.3 million a year ago. Basic loss per share from continuing operations was USD 65.25 compared to USD 56 a year ago.